Verona Pharma plc VRNA

$ 41.98 1.83%

Quarterly report 2024-Q3
added 11-04-2024

Verona Pharma plc Balance Sheet 2011-2024 | VRNA

Annual Balance Sheet Verona Pharma plc

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-222 M	-217 M	-143 M	-188 M	-22 M	-19.8 M	-31.4 M	-49.1 M	-5.22 M	-15.5 M	-996 K	-1.55 M	-3.92 M
Long Term Debt	48.4 M	9.77 M	4.87 M	-	491 K	-	-	-	-	-	-	-	-
Long Term Debt Current	1.18 M	675 K	648 K	798 K	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	50.1 M	9.97 M	5.16 M	5.15 M	1.65 M	1.1 M	1.03 M	990 K	-	-	-	-	-
Total Current Liabilities	8.69 M	19 M	33.4 M	14.2 M	-	-	-	-	-	-	-	-	-
Total Liabilities	58.8 M	29 M	38.6 M	19.4 M	45.1 M	74.3 M	89.5 M	14.4 M	2.69 M	816 K	807 K	322 K	242 K
Deferred Revenue	-	-	-	-	60 K	106 K	152 K	-	-	-	-	-	-
Retained Earnings	-388 M	-333 M	-264 M	-	-	-	-	-35.4 M	-34.2 M	-24.5 M	-21.7 M	-17.2 M	-12.7 M
Total Assets	308 M	259 M	187 M	204 M	45.1 M	74.3 M	89.5 M	56.9 M	11 M	20.4 M	4.22 M	4.53 M	6.53 M
Cash and Cash Equivalents	272 M	228 M	148 M	188 M	30.4 M	-	-	-	-	-	-	-	-
Book Value	249 M	230 M	148 M	185 M	-	-	-	42.5 M	8.28 M	19.6 M	3.41 M	4.21 M	6.29 M
Total Shareholders Equity	249 M	230 M	148 M	185 M	42.7 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Verona Pharma plc

	2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	120 M	120 M	48.4 M	19.9 M	19.9 M	19.8 M	9.77 M	5.04 M	4.98 M	4.93 M	4.87 M	4.82 M	4.77 M	4.68 M	4.64 M	4.64 M	4.64 M	4.64 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	223 M	218 M	50.1 M	19.9 M	19.9 M	19.9 M	9.97 M	5.26 M	5.11 M	5.1 M	5.16 M	5.62 M	5.74 M	5.04 M	5.15 M	5.15 M	5.15 M	5.15 M	652 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	251 M	266 M	58.8 M	28.9 M	30.8 M	46.4 M	29 M	37.4 M	44 M	43 M	38.6 M	33.4 M	64.1 M	17.7 M	19.4 M	19.4 M	19.4 M	19.4 M	13.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	169 K	21.3 M	-	-	-	-	-	-	-	-	-	-	40.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-528 M	-485 M	-388 M	-374 M	-359 M	-350 M	-333 M	-322 M	-307 M	-289 M	-264 M	-240 M	-251 M	-228 M	-207 M	-207 M	-207 M	-207 M	-142 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	382 M	434 M	308 M	292 M	304 M	323 M	259 M	275 M	155 M	169 M	187 M	202 M	219 M	190 M	204 M	204 M	204 M	204 M	56.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	336 M	405 M	272 M	257 M	271 M	291 M	228 M	232 M	112 M	133 M	148 M	167 M	146 M	170 M	188 M	188 M	188 M	188 M	30.4 M	-	-	-	25.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	130 M	168 M	249 M	264 M	273 M	277 M	230 M	237 M	111 M	126 M	148 M	168 M	154 M	172 M	185 M	185 M	185 M	185 M	42.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	130 M	168 M	249 M	264 M	273 M	277 M	230 M	237 M	111 M	126 M	148 M	168 M	154 M	172 M	185 M	185 M	185 M	185 M	42.7 M	-	-	-	78.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency